Document:

Exhibit 10.3

 

January 18, 2015

 

Michael du Toit

 

Dear Michael,

 

On behalf of Everyday Health, Inc. (the “Company”),
I am pleased to offer you the full-time position of President, reporting to Ben Wolin. The terms of your employment relationship
with the Company will be set forth below.

 

Cash Compensation: Your start date is expected to be February
2, 2015, but the actual start date may change upon mutual agreement of the parties. During calendar year 2015, your annual base
salary will be four hundred thousand dollars ($400,000) and during calendar year 2016, your annual base salary will be four hundred
and twenty five thousand dollars ($425,000). You are an exempt employee and therefore not eligible to receive overtime pay. Company
employees are paid semi-monthly on the 15th and end of the month. The Company shall also pay you a “sign-on”
bonus in the amount of $200,000, payable by February 15, 2015.

 

You are eligible to receive an annual performance bonus, and the
target for this annual performance bonus is 100% of your base salary (i.e. $400,000 for 2015). For calendar year 2015 and 2016,
the bonus structure will be as follows: (i) 50% will be based on the Company’s total 2015 and 2016 revenue, as applicable,
measured against the Board-approved revenue goal for the relevant year; and (ii) 50% will be based on the Company’s total
2015 and 2016 adjusted EBITDA, as applicable, measured against the Board-approved adjusted EBITDA goal for the relevant year. The
calculation of the final performance bonus payout amounts based on the Company’s revenue and adjusted EBITDA relative to
the Board-approved goals (e.g. tiered payouts based on actual performance relative to goal) shall be consistent with the structure
approved by the Company’s Compensation Committee for the other senior executives. Annual bonuses are paid by the Company
in the latter half of the first calendar quarter, following completion of the annual audit for the prior calendar year. Notwithstanding
the foregoing, the Company will guarantee 25% of your 2015 bonus target (i.e. $100,000) regardless of the Company’s financial
performance. The Board-approved revenue and adjusted EBITDA goals are subject to appropriate pro forma adjustment in the event
of acquisition or other similar corporate events during the course of the year.

 

Employee Benefits: You will be eligible for the benefits
package that the Company offers to its regular, full time employees, subject to the terms and conditions of the applicable benefits
plan. These benefits include participation in the Company’s 401k plan and the Company’s Employee Stock Purchase Plan
(ESPP). The details of this package have been, or will be, sent to you electronically.

 

Equity Compensation: In connection with your hiring you will
receive a grant of 110,000 restricted stock units (RSUs) pursuant to the Company’s 2014 Equity Incentive Plan. Twenty

    	1

    	

    

percent of the RSUs subject to this award (i.e. 22,000 RSUs) will
vest on November 15, 2015; forty percent of the RSUs subject to this award (i.e. 44,000 RSUs) will vest on November 15, 2016; and
forty percent of the RSUs subject to this award (i.e. 44,000 RSUs) will vest on November 15, 2017.

 

In addition to the RSU award described in the preceding paragraph,
you shall receive a grant of 40,000 RSUs in the first quarter of 2015. The vesting of this award shall be linked to the Company’s
2015 financial performance as follows: (i) 10,000 of such RSUs shall vest on March 31, 2016 if, and only if, the Company’s
total revenue for 2015 (based on the Company’s annual audit) equals or exceeds the Board-approved revenue goal for 2015;
(ii) 10,000 of such RSUs shall vest on March 31, 2016 if, and only if, the Company’s total adjusted EBITDA for 2015 (based
on the Company’s annual audit) equals or exceeds the Board-approved adjusted EBITDA goal for 2015; (iii) 10,000 of such RSUs
shall vest on March 31, 2016 if, and only if, the Company’s total revenue for 2015 (based on the Company’s annual audit)
equals or exceeds 102.5% of the Board-approved revenue goal for 2015; and (iv) 10,000 of such RSUs shall vest on March 31, 2016
if, and only if, the Company’s total adjusted EBITDA for 2015 (based on the Company’s annual audit) equals or exceeds
102.5% of the Board-approved adjusted EBITDA goal for 2015; provided, however, that in the case of (iii) and (iv) above, in the
event that the Company’s total revenue or adjusted EBITDA falls between the Board-approved target and 102.5% of the Board-approved
target, then a proportionate share of the relevant RSUs shall vest. By way of example, if the total revenue for 2015 falls halfway
between the Board-approved target and 102.5% of the Board-approved target, then 5,000 RSUs shall vest under (iii) above.

 

Similarly, you shall receive a grant of 40,000 RSUs in the first
quarter of 2016. The vesting of this award shall be linked to the Company’s 2016 financial performance as follows: (i) 10,000
of such RSUs shall vest on March 31, 2017 if, and only if, the Company’s total revenue for 2016 (based on the Company’s
annual audit) equals or exceeds the Board-approved revenue goal for 2016; (ii) 10,000 of such RSUs shall vest on March 31, 2017
if, and only if, the Company’s total adjusted EBITDA for 2016 (based on the Company’s annual audit) equals or exceeds
the Board-approved adjusted EBITDA goal for 2016; (iii) 10,000 of such RSUs shall vest on March 31, 2017 if, and only if, the Company’s
total revenue for 2016 (based on the Company’s annual audit) equals or exceeds 102.5% of the Board-approved revenue goal
for 2016; and (iv) 10,000 of such RSUs shall vest on March 31, 2017 if, and only if, the Company’s total adjusted EBITDA
for 2016 (based on the Company’s annual audit) equals or exceeds 102.5% of the Board-approved adjusted EBITDA goal for 2016;
provided, however, that in the case of (iii) and (iv) above, in the event that the Company’s total revenue or adjusted EBITDA
falls between the Board-approved target and 102.5% of the Board-approved target, then a proportionate share of the relevant RSUs
shall vest. By way of example, if the total revenue for 2016 falls halfway between the Board-approved target and 102.5% of the
Board-approved target, then 5,000 RSUs shall vest under (iii) above.

 

As with the annual bonus calculation described above, the Board-approved
revenue and adjusted EBITDA goals are subject to appropriate pro forma adjustment in the event of acquisition or other similar
corporate events during the course of the year.

    	2

    	

    

With respect to all the RSU awards detailed above, if you remain
in continuous service at the time of a “Corporate Transaction” (as defined in the 2014 Equity Incentive Plan), 50%
of the then-unvested RSUs will become vested and exercisable as of immediately prior to the closing of such transaction. Beginning
in 2017, you shall be eligible to receive additional equity-based awards like other senior executives of the Company, subject to
the final approval of the Company’s Compensation Committee. Historically, such awards have been granted in the first calendar
quarter of the year in connections with the Company’s annual employee performance review process.

 

Severance: If the Company terminates your employment without
Cause (as defined below), and other than as a result of your death or disability, and provided such termination constitutes a “separation
from service” (as defined under Treasury Regulation Section 1.409A-1(h)), then subject to your obligations below, the Company
will pay to you, as severance, an amount equal to (i) twelve (12) months of your then-current base salary and (ii) your annual
performance bonus target amount (collectively, the “Severance Benefits”). In addition, you will receive the Severance
Benefits if you resign from employment with the Company for “Good Reason” within ten (10) days after the occurrence
of one of the events specified in the definition of Good Reason, by giving notice that you intend to terminate your employment
for Good Reason on the thirtieth (30) day following the Company’s receipt of your notice, if the Company has not cured the
event that gives rise to Good Reason before the end of such thirty (30) day period. The Severance Benefits are conditional upon
(a) your continuing to comply with your obligations under your Agreement to Protect Information, Assign Inventions, and Prevent
Unfair Competition and Unfair Solicitation (the “Confidentiality Agreement”) during the period of time in which you
are receiving the Severance Benefits and (b) your delivering to the Company an effective, general release of claims in favor of
the Company in a form acceptable to the Company within 30 days following your termination date. The Severance Benefits will be
paid on the Company’s regular payroll schedule over the 12 month period immediately following your termination date, and
will be subject to applicable tax withholdings; provided, however, that no payments will be made prior to the 30th day following
your termination date. In addition to the Severance Benefits, in the event of a termination without Cause by the Company or your
termination of employment for Good Reason, any remaining unvested RSUs that were part of the initial grant of 110,000 time-based
RSUs referenced above shall be vested as of the employment termination date.

 

For purposes of this Agreement, “Cause” means (A) your
conviction (including a guilty plea or a no contest plea) of a felony, or of any other crime involving fraud, dishonesty or moral
turpitude; (B) your attempted commission of or participation in a fraud or act of material dishonesty against the Company; (C)
your material breach of any written agreement between you and the Company (including but not limited to your Confidentiality Agreement);
or (D) your refusal to follow a clear and lawful directive of the Chief Executive Officer or Board of Directors or your habitual
neglect of your duties, provided that if Cause is based on the occurrence of an event specified in (D) above, the Company will
give you written notice that the Company intends to terminate your employment for Cause on the thirtieth (30th) day following your
receipt of the Company’s notice, if you have not cured the circumstances constituting Cause before the end of such thirty
(30) day period.. For purposes of this Agreement, “Good Reason” means the occurrence
of any of the following without your prior written consent: (i) a reduction by the Company in your base

    	3

    	

    

salary or target bonus; (ii) the assignment to you of any duties
or responsibilities which result in the material diminution of your then current position; or (iii) relocation of your principal
place of business more than fifty (50) miles from its current location.

 

It is intended that all of the Severance Benefits payable under
this letter satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury
Regulations 1.409A-1(b)(4) and 1.409A-1(b)(9), and this letter will be construed to the greatest extent possible as consistent
with those provisions. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section
1.409A-2(b)(2)(iii)), your right to receive any installment payments under this letter (whether severance payments, reimbursements
or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder
shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this letter,
if you are deemed by the Company at the time of your separation from service to be a “specified employee” for purposes
of Code Section 409A(a)(2)(B)(i), and if any of the payments upon separation from service set forth herein are deemed to be “deferred
compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited
distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be
provided to you prior to the earliest of (i) the expiration of the six-month period measured from the date of your Separation from
Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition
of adverse taxation. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period,
all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid
as otherwise provided herein.

 

Business Expenses: All approved business expenses will be
reimbursed, following submission of an approved expense report approved by your manager. During the time your primary residence
is in the Philadelphia, Pennsylvania area, the Company will provide you with housing in Manhattan (either access to a residence
that is rented by the Company or reimbursement of hotel accommodations) for use during the business week and other business uses.
The tax treatment for such housing allowance, and any public disclosure in the Company’s securities filings, shall be consistent
with applicable tax and securities laws.

 

Non-Disclosure and Developments Agreement: Like all Company
employees, you will be required to sign the Company’s standard “Agreement to Protect Information, Assign Inventions,
and Prevent Unfair Competition and Unfair Solicitation” as a condition of employment. In addition, you will be required to
abide by the Company’s strict policy that prohibits any new employee from using or bringing with him or her from any previous
employer any confidential information, trade secrets, or proprietary materials or processes of such former employer.

 

At-Will Employment: This letter does not constitute a guarantee
of employment or an employment contract for any specified period of time. You will be an employee-at-will, meaning that either
you or the Company may terminate your employment relationship at any time, without notice, for any reason or no reason.

    	4

    	

    

Federal Immigration Law: For purposes of federal immigration
law, you are required to provide to the Company documentary evidence of your identity and eligibility for employment in the United
States. Documentation must be provided to us within three (3) business days of your commencement date, or our employment relationship
with you may be terminated.

 

We are pleased that you are joining our team to work with us to
help the Company reach its full potential. Please confirm your acceptance of this offer by signing and emailing one copy of this
letter to me at ashapiro@everydayhealthinc.com. If you have any questions, please feel free to contact me at (646)-728-9715.

 

Sincerely,

 

	/s/ Alan Shapiro	 
	Alan Shapiro	 
	EVP, General Counsel

 

The foregoing terms and conditions are hereby accepted:

 

	Employee Signature:	/s/ Michael du Toit	 
	 	 	 
	Name: 	Michael du Toit
	 	 	 
	Date:	January 18, 2015

    	5Exhibit 10.4

 

February 3, 2015

 

Paul Slavin

Chief Operating Officer

Everyday Health, Inc.

345 Hudson Street, 16th Floor

New York City, NY 10014

 

Dear Paul:

 

While the Everyday Health, Inc. (“Company”)
management team and Board of Directors (“Board”) will miss your involvement in day-to-day operations and strategic
vision, we understand your desire to put in place a transition plan at this time. As you prepare for your next endeavors, it is
with tremendous gratitude for your friendship, service and leadership that I am pleased to set forth below the terms of your transition.
These terms are referred to herein as the “Agreement.”

 

1. Separation Date. We
have agreed that your last day of employment with the Company and your employment termination date will be March 31, 2015 (the
“Separation Date”). From February 1, 2015 through March 31, 2015, you shall serve as Executive Vice President, Special
Advisor to the Chief Executive Officer. This Agreement shall supersede the employment letter between you and the Company dated
August 17, 2011, as amended on February 25, 2013 (collectively, the “Employment Letter”), and the Employment Letter
is hereby terminated with no further force or effect.

 

2. Transition Period
and Duties. Beginning April 1, 2015 and continuing through and including September 30, 2016 (the “Advisory Period”),
you have agreed to provide advisory

    	 

    	

    

and transition services to the Company. It is expected that the advisory and transition services
shall focus on representing the Company at external media and other functions, assisting the Company maintain excellent relations
with the celebrities and public personalities that partner with the Company and assist the Company with business development activities
across the media community. During the Advisory Period, you shall also serve as a member of the Company’s Advisory Board
and participate in all activities of such Advisory Board. During the Advisory Period, in light of the change in your role, you
will no longer have, and will not represent that you have, legal authority to act on behalf of or to bind the Company. You understand
and agree that the services you provide during the Advisory Period shall not operate to create a contract of employment with the
Company. Further, such services will be provided by you as an independent contractor to the Company. Through May 31, 2015, the
Company shall provide office space to you and assistant support, as well as the general administrative services of the office (including
your existing Company email address).

    	 

    	

    

3. Accrued Salary.
On or before the first regularly scheduled payroll date following the Separation Date, the Company will pay you all accrued salary
earned through the Separation Date, subject to standard payroll deductions and required withholdings.

 

4. Separation Payment.
Pursuant to the terms of your offer letter dated August 17, 2011 and amended as of February 25, 2013, and provided you execute
and do not revoke this Agreement, you will receive separation pay equal to $350,000.00, less applicable withholdings, which amount
is equal to twelve months of your current base salary, paid as continued salary on the Company’s regular payroll schedule
over the twelve months following your Separation Date. Because you are specified employee within the meaning of Internal Revenue
Code Section 409A(a)(2)(B)(i), the payment of this amount will be delayed for a period of six months until October 1, 2015. On
the next regular payroll on or following October 1, 2015, you will receive a lump sum payment equal to the amount of base salary
you would have received between April 1, 2015 and the date on which the payment is made and thereafter shall continue to receive
your base salary pursuant to the Company’s regular payroll schedule through March 31, 2016.

 

5. Advisory Services
Fee.

 

(a) Transition
Payment. The Company will pay you, as part of the transition, the gross amount of Five Hundred Thousand Dollars ($500,000.00),
subject to required withholdings. This amount will be paid in two installments - $250,000 by April 15, 2015 and the remaining $250,000
by June 1, 2015.

 

(b) Advisory
Services Fee. The Company will pay you a fee in the amount of Two Hundred Fifty Thousand Dollars ($250,000.00) as additional consideration
hereunder by September 1, 2015. This fee shall not be subject to withholdings and will be reported by the 

    	 

    	

    

Company to the IRS via
Form 1099. You understand and agree that you will be responsible for all taxes associated with such fee.

 

6. Stock Options.
All outstanding options granted to you under the Company’s 2003 Stock Option Plan (the “Plan”) shall continue
to vest during the Advisory Period. As part of this Agreement, the Company shall permit you (or in the event of your death or disability,
your heirs, executors and legal representatives, as applicable) to exercise any or all of your vested options as of the end of
the Advisory Period on or before September 30, 2017. Except as stated herein, your options shall be subject to the terms of the
Plan and grant documents.

 

7. Health Benefits.
You shall have the option to continue health coverage in accordance with the Consolidated Omnibus Budget Reconciliation Act (“COBRA”),
and you will be provided with a separate letter addressing your rights to purchase continuing health coverage and the costs associated
therewith. In the event you elect to participate in COBRA, the Company will pay your health insurance premiums pursuant to COBRA
for a period not to exceed eighteen (18) months from the Separation Date.

 

8. No Other Compensation
or Benefits. You acknowledge that, except as expressly provided in this Agreement, the Company is not obligated to provide
you with any additional compensation, severance, or benefits after the Separation Date. Specifically, you understand and agree
that the compensation and benefits provided to you in this Agreement are in lieu of and not in addition to any other compensation
or benefit to which you may otherwise be entitled to, including, but not limited to, the compensation and benefits provided for
in the Employment Letter.

 

9. Expense Reimbursements.
You agree that, within 30 days of the Separation

    	 

    	

    

Date, you will submit any final documented expenses incurred through the Separation
Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business
practice. The Company will reimburse reasonable expenses incurred in connection with your duties during the Advisory Period pursuant
to its regular business practice.

 

10. Return of Company
Property. By September 30, 2016, unless requested earlier by the Company, you agree to use commercially reasonable efforts
to return to the Company or delete all tangible Company documents (and all tangible copies thereof) and other tangible Company
property that you have in your possession, including, but not limited to, Company files, notes, records, business plans and forecasts,
and financial information, and any tangible materials of any kind that contain or embody any proprietary or confidential information
of the Company (and all tangible reproductions thereof).

 

11. Confidential Information
Obligations and Restrictive Covenants.

 

(a) You
understand and agree that, after the Separation Date and during and after the Advisory Period, you shall hold in strict confidence
and shall not disclose, directly or indirectly, to any third party, person, firm, corporation or other entity, irrespective of
whether such person or entity is a competitor of the Company or is engaged in a business similar to that of the Company, any Confidential
Information (as defined below) of the Company or any subsidiary of the Company obtained or developed by you from, through, or in
the course of your employment with the Company or your services hereunder. “Confidential Information” means any information
used by or belonging or related to the Company or any of its affiliates that is not known generally to the industry in which the
Company is or may be engaged and which the

    	 

    	

    

Company maintains on a confidential basis including without limitation any and all intellectual
property, trade secrets and proprietary information, information relating to the Company’s business and services, employee
information, customer lists and records, business processes, procedures or standards, know-how, technology, business strategies,
records, financial information, in each case whether or not reduced to writing or stored electronically, as well as any information
that the Company advises you should be treated as confidential information (including information conceived, discovered or developed
by you), that you learn of, possess, or have access through your employment by the Company or your services under this Agreement,
related to the Company, its business partners, or the business of its customers or potential customers.

 

(b) Notwithstanding
the foregoing limitations, you shall not be required to keep confidential any information that: (i) is known or available through
other lawful sources, or (ii) is or becomes publicly available or generally known in the industry through no fault of yours, your
agents or another individual or entity that owes a duty of confidentiality to the Company, or (iii) is required to be disclosed
pursuant to any statutes, laws, rules, regulations, ordinances, codes, directives, writs, injunctions, decrees, judgments, and
orders of any governmental body (provided the Company is given reasonable prior notice).

 

(c) Notwithstanding
anything in this Agreement to the contrary, you understand and agree that the assignment of inventions provided for in Section
4 of your Agreement to Protect Confidential Information, Assign Inventions, and Protect Unfair Competition and Unfair Solicitation
(“Assignment and Disclosure of Inventions”) remains effective. You also agree to continue to cooperate with the Company,
at the Company’s sole cost and expense, both during and after employment and after your services under this

    	 

    	

    

Agreement, with
respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in
the United States and foreign countries) relating to assigned inventions. This includes signing all papers, including, without
limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights,
and powers of attorney, which are reasonably necessary in order to protect its rights and interests. You further agree that if
the Company is unable, after reasonable effort, to secure your signature on any such papers, any officer of the Company shall be
entitled to execute any such papers as your agent and attorney-in-fact, and you hereby irrevocably designate and appoint each officer
of the Company as your agent and attorney-in-fact to execute any such papers on your behalf, and to take any and all actions which
may be reasonably necessary to protect the Company’s rights and interests in any assigned invention.

 

(d) You
further understand and agree that through the Advisory Period, you will not, as an officer, director, employee, consultant, owner,
partner, or in any other capacity, either directly or through others, without the written approval of the Company:

 

(1) perform services for
the following entities and any of their subsidiaries: (i) Remedy Health; (ii) Healthgrades; (iii) Sharecare; (iv) Athena Health;
and (v) Physicians Interactive.

 

(2) interfere with or disrupt,
or attempt to interfere with or disrupt, the relationship, contractual or otherwise, between the Company, or any subsidiary of
the Company, and any customer, vendor, licensor, or supplier of the Company or any subsidiary of the Company; or

    	 

    	

    

(3) solicit for employment
or offer employment to (directly or indirectly, individually or in connection with any new employer or other business partner)
any person who is a then current employee of the Company or any subsidiary of the Company or has left the Company or any subsidiary
of the Company in the preceding three (3) months.

 

Notwithstanding the foregoing,
for three years following the Separation Date, you will not, as an officer, director, employee, consultant, partner, or in any
other capacity, either directly or through others, without the written approval of the Company: (i) perform services for WebMD
and/or any of its subsidiaries; or (ii) work with any of the celebrities and public personalities that were partners with the Company
during your employment with the Company or that you engage with as part of the advisory services that you provide the Company.

 

10. Confidentiality.
The provisions of this Agreement will be held in strictest confidence by you and the Company and will not be publicized or disclosed
in any manner whatsoever; provided, however, that: (a) you may
disclose this Agreement in confidence to your immediate family, prospective employers and business partners, and financing sources;
(b) the parties may disclose this Agreement in confidence to their respective attorneys, accountants, auditors, tax preparers,
and financial advisors; (c) the Company may disclose this Agreement
as necessary to fulfill standard or legally required corporate reporting or disclosure requirements, including but not limited
to, Securities and Exchange Commission filings; and (d) the parties may disclose this Agreement insofar as such disclosure may
be necessary to enforce its terms or as otherwise required by law.

 

11. Non-disparagement.
The Company shall instruct its officers and directors not to disparage you in any manner or through any medium likely to be harmful
to you or your

    	 

    	

    

business, business reputation or your personal reputation. You agree not to disparage the Company and its officers
and directors, in any manner or through any medium likely to be harmful to them or their business or business reputation each as
related to the Company and its subsidiaries. In the event that either party violates the non-disparagement obligation (or, in the
case of the Company, any of its officers or directors fail to abide by the above instruction), the other party shall be permitted
to respond as they reasonably believe appropriate under the circumstances without being limited by the above restrictions.

 

12. No Admissions.
You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission
of any liability by the Company to you or to any other person, and that the Company makes no such admission.

 

13. Release of Claims.
In exchange for the mutual release provided for in this Section 13, except as provided herein, you hereby generally and completely
release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors,
parent and subsidiary entities, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown,
that arise out of or are in any way related to events, acts, conduct or omissions occurring with respect to your relationship
with the Company at any time prior to and including the date you sign this Agreement. This general release includes, but is not
limited to claims under: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; Sections 1981 through
1988 of Title 42 of the United States Code, as amended; the Employee Retirement Income Security Act of 1974, as amended; the Americans
with Disabilities Act of 1990, as amended; the Age Discrimination in Employment Act of 1967, as amended (“ADEA”);
New York Human Rights Laws, as amended; the New York Civil Rights Act, as amended; the New York Minimum Wage Law, as amended;

    	 

    	

    

Equal Pay Law for New York, as amended; any other federal, state or local civil or human rights law or any other local, state
or federal law, regulation or ordinance; and any public policy, contract, tort, or common law. The foregoing release does not
encompass, and you do not release: (i) any and all claims or rights that you may have with respect to your capacity as a stockholder
or optionholder of the Company, including under any stockholder agreement, option plan or option grant documents and similar instruments;
(ii) claims and rights to indemnification, contribution or insurance arising from your service as an employee, officer, director,
stockholder or optionholder of the Company; or (iii) your rights under this Agreement. Upon request by the Company, on or after
the Separation Date, you shall re-execute the release of claims set forth in this Section in order to effectuate a full release
of claims through the Separation Date.

 

In exchange for the mutual
release provided for in this Section 13, except as provided herein, the Company on behalf of itself and its directors, officers,
employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, affiliates, and
assigns hereby generally and completely release you and your family members, affiliates, successors and assigns from any and all
claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct
or omissions occurring with respect to your relationship with the Company or service as an officer or director of the Company,
at any time prior to and including the date you sign this Agreement. This general release includes, but is not limited to claims
under: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; Sections 1981 through 1988 of Title
42 of the United States Code, as amended; the Employee Retirement Income Security Act of 1974, as amended; the Americans with Disabilities
Act of 1990, as amended; the Age Discrimination in Employment Act of 1967, as amended (“ADEA”); New York Human Rights
Laws, as amended;

    	 

    	

    

the New York Civil Rights Act, as amended; the New York Minimum Wage Law, as amended; Equal Pay Law for New York,
as amended; any other federal, state or local civil or human rights law or any other local, state or federal law, regulation or
ordinance; and any public policy, contract, tort, or common law. The foregoing release does not encompass, and the Company does
not release its rights under this Agreement.

 

14. Indemnification.
You shall be entitled to the benefits of all provisions of the Certificate of Incorporation of the Company, as amended, and the
Bylaws of the Company, as amended, that provide for indemnification, exculpation, contribution and reimbursement of officers,
directors and/or employees of the Company. In addition, without limiting such provisions of the Certificate of Incorporation or
Bylaws, or any other agreement with the Company, to the fullest extent permitted by law, the Company shall indemnify you and save
and hold you harmless from and against, and pay or reimburse, any and all claims, demands, liabilities, costs and expenses, including
judgments, fines or amounts paid on account thereof (whether in settlement or otherwise), and reasonable expenses, including attorneys’
fees actually and reasonably incurred, if you are made a party to or witness in any action, suit or proceeding, or if a claim
or liability is asserted against you (whether or not in the right of the Company), by reason of the fact that you are or were
a director, officer, employee, consultant, advisor or acted in such capacity on behalf of the Company, or the rendering of services
by you pursuant to this Agreement or any of your prior employment agreements with the Company (including the Employment Letter),
whether or not the same shall proceed to judgment or be settled or otherwise brought to a conclusion. Upon your request, the Company
will advance any reasonable expenses or costs, subject to your undertaking to repay any such advances in the event there is an
unappealable final determination that you are not entitled to indemnification for

    	 

    	

    

such expenses. This provision shall survive
the expiration or termination of this Agreement.

 

15. Application of Section
409A. To the extent that any payments and benefits provided under this Agreement constitute “deferred compensation”
within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (“Code”) and the regulations and
other guidance thereunder and any state law of similar effect (collectively, “Section 409A”), such payments and benefits
shall not commence in connection with your termination of employment unless and until you have also incurred a “separation
from service” (as such term is defined in Treasury Regulation Section 1.409A-1(h)) unless the Company reasonably determines
that a separation from service is not a necessary precondition to payment and as a result such amounts may be provided to you without
causing you to incur the additional 20% tax under Section 409A. For the sake of clarity, it is intended that you incur a separation
from service on the Separation Date, and the parties acknowledge that the amount of the advisory and transition services to be
provided during the Advisory Period shall be at a level that is not greater than (and may be less than) 20% of the average level
of services you provided over the thirty-six (36) months immediately preceding the Advisory Period. It is further intended that
each installment of pay and benefits provided for in this Agreement is a separate “payment” for purposes of Treasury
Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments set forth in this Agreement satisfy,
to the greatest extent possible, the exceptions from the application of Section 409A provided under Treasury Regulation Sections
1.409A-1(b)(4), 1.409A-1(b)(5), and 1.409A-1(b)(9).

 

To the extent any indemnification
payment, expense reimbursement, or the provision of any in-kind benefit is determined to be subject to Section 409A (and not exempt
pursuant to Treasury Regulation § 1.409A-1(b)(9)(v)(A) or (C) or otherwise), the amount of any such

    	 

    	

    

indemnification payment
or expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the indemnification
payment or provision of in-kind benefits or expenses eligible for reimbursement in any other calendar year (except for any life-time
or other aggregate limitation applicable to medical expenses), and in no event shall any indemnification payment or expenses be
reimbursed after the last day of the calendar year following the calendar year in which you incurred such indemnification payment
or expenses, and in no event shall any right to indemnification payment or reimbursement or the provision of any in-kind benefit
be subject to liquidation or exchange for another benefit.

 

16. General Provisions.
This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with
regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than
those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may
not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement
will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of
both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid
or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision
in question will be modified so as to be rendered enforceable. This Agreement will be deemed to have been entered into and will
be construed and enforced in accordance with the laws of the State of New York as applied to contracts made and to be performed
entirely within New York. Any dispute arising out of this Agreement shall be brought in the state or federal courts of the State
of New York, which shall serve as the exclusive forum for any such dispute. Any ambiguity in this

    	 

    	

    

Agreement shall not be construed
against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be
a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as original
signatures.

 

If this Agreement is acceptable to you, please
sign below and return the original to me.

 

We wish you the best in your future endeavors.

 

Sincerely,

 

Everyday
Health, Inc.

 

	By:	/s/ Alan Shapiro	 
	 	Name: 	Alan Shapiro	 
	 	Title:	EVP & General Counsel

 

I have
read, understand and agree fully to the foregoing Agreement:

 

	/s/ Paul Slavin	 
	Paul Slavin

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]